Masayasu Takada

Control of postprandial hyperglycaemia by galactosyl maltobionolactone and its novel anti-amylase effect in mice.

The ability to control carbohydrate digestion is useful in the treatment of diabetes mellitus and obesity. In the present study, we examined whether recently developed 4(2)-O-beta-D-galactosyl maltobionolactone (LG2O) having anti-amylase activity is able to control postprandial blood glucose concentration in mice. In addition, we tried to determine how LG2O regulates carbohydrate delivery in the gut lumen by conducting in vivo and in vitro studies. Male non-diabetic ddY mice and KK-A(y) mice, a spontaneously diabetic strain, had free access to a carbohydrate rich diet supplemented with LG2O (3 or 10 g/kg) for 0.5 hr, and blood glucose concentration was measured. LG2O suppressed any steep increase in postprandial blood glucose concentration in both ddY and KK-A(y) mice. Corresponding to the blood glucose response, LG2O also markedly suppressed any increase in postprandial plasma insulin concentration. After ingestion of the diet, LG2O produced a 1.5-3.5 fold increase in the gut contents and reducible sugar content in the small intestine but not in the stomach. Although alpha-amylase activity in the stomach was much lower compared with the activity in the small intestine, LG2O still strongly inhibited alpha-amylase activity in the stomach. In contrast, LG2O had little or no influence on alpha-amylase activity in the proximal intestine. From the in vitro carbohydrate digestion stimulation, LG2O at 7.5 mM decreased glucose production by 75% for dextrin, 25% for alpha-starch and 60% for raw starch. In conclusion, administration of LG2O inhibits carbohydrate digestion in the gut, and produces significant improvements in both blood glucose and insulin response following ingestion as part of the diet, and this evidence provides support for its therapeutic potential in treating diabetes mellitus and obesity.

Gene cloning and enzymatic characteristics of a novel γ-cyclodextrin-specific cyclodextrinase from alkalophilic Bacillus clarkii 7364

A new gene, cda, was found in the downstream region of the cgt gene encoding cyclodextrin (CD) glucanotransferase from Bacillus clarkii 7364. Cda encoded by the cda was a cyclodextrinase that has extremely high specificity for gamma-CD. The rates of hydrolysis toward alpha- and beta-CD, maltooctaose and polysaccharides were less than 4% of that toward gamma-CD. Cda also has a transglycosylation activity, by which the maltotriose moiety was transferred from maltohexaose and maltopentaose. The comparison of the amino acid sequences between Cda and CD-degrading enzymes revealed the sequence of Cda has unique features. One of them is Gly247 next to the catalytic nucleophile Asp246. Most enzymes in GH family 13 have more bulky amino acids at this position. Other features in Cda are the lack of the N-domain in CD-degrading enzymes involving in the dimerization contributing to the preference of CDs and the existence of a long extra sequence in the C-terminus. Despite the lack of N-domain, Cda showed a dodecameric structure. The long extra sequence in the C-terminus might contribute to the oligomerization of Cda through a new mechanism. These unique features indicate that Cda is a novel type of CD-degrading enzyme.

Inhibition of Human α-Amylases By Synthetic 63-O-Benzyl-and 63-O-β-D-Galactosyl Maltotrionolactones

ABSTRACT Maltooligosaccharides were transformed into both endo-modified oligosaccharidonolactones as substrate analogue inhibitors for human α-amylases. p-Nitrophenyl 65-O-benzyl-α-maltopentaoside (1) and p-nitrophenyl 65-O-β-D- galactosyl-α-malto-pentaoside (11), which have been synthesized as substrates for human α-amylases in serum, were selectively hydrolyzed by specific α-amylases to afford 63-O-benzyl maltotriose (8) and 63-O-β-D-galactosyl maltotriose (10), respectively. Both the modified oligomers were chemically oxidized to 63-O-benzyl maltotrionolactone (6) and 63-O-β-D-galactosyl maltotrionolactone (7), respectively. Compound 6, which is a strong competitive inhibitor, had K i values of 2.8 and 9.6 x 10−6M for human salivary α-amylase (HSA) and human pancreatic α-amylase (HPA), respectively. On the other hand, the inhibition activity of 7 was about ten times less than 6. These results indicated that the 6-O-substituted hydrophobic benzyl group enhances the binding with enzymes, whereas the corr...

Crystallization and preliminary X-ray study of γ-­type cyclodextrin glycosyltransferase from Bacillus clarkii

A gamma-cyclodextrin glycosyltransferase (EC 2.4.1.19) from Bacillus clarkii was crystallized using the hanging-drop vapour-diffusion method at 293 K. X-ray diffraction data were collected to 2.2 A. The crystal belongs to space group R3, with unit-cell parameters a = b = 211.6, c = 52.7 A. The asymmetric unit contains one protein molecule, with a corresponding V(M) of 3.03 A(3) Da(-1) and a solvent content of 59.4%. Molecular replacement was successfully carried out using a homology model based on the three-dimensional structure of the CGTase from Thermonanaerobacterium thermosulfurigenes EM1 as a search model.